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Abstract 
Objective: Determine if additional non-random 
biopsies beyond clinician directed biopsy 
enhance the detection of high-grade cervical 
disease. 
Methods: A cervical imaging system (CIS) was 
used as an adjunct to colposcopy in an 
academic colposcopy clinic between July 2008 
and October 2010 in an IRB approved post-FDA 
approval study. A post hoc analysis explored if 
additional biopsies through the CIS added 
diagnostic value to the clinician’s biopsies.  
Results: Of 181 women with complete analysis, 
50 (27.6%) were found to have CIN2+ disease. 
Clinician directed biopsy detected 45 of 50 
(90%) of CIN2+. CIS directed biopsy detected 
an additional 5 of 50 (10%) of CIN2+.  
Clinicians directed 180 total biopsies meaning 
that 1 of every 4 clinician biopsies detected 
CIN2+ disease, whereas CIS directed an 
additional 68 biopsies resulting in a yield of one 
case of CIN2+ disease for approximately 14 
additional biopsies.  
Conclusion: Additional non-random biopsies 
based on CIS increased the detection of high-
grade disease in cases where clinicians did not 
identify high-grade disease. As noted by others, 
both random and non-random additional 
biopsies increase the sensitivity of traditional 
colposcopy. What is not clear is whether the 
additional cases identified represent clinically 
significant disease. Our study is particularly 
relevant as colposcopists explore standardizing 
high yield diagnostic techniques. 
1University of Iowa Hospitals and Clinics, 
Department of Obstetrics and Gynecology, Iowa 
City, Iowa 
 
Background 
Colposcopy with biopsy and histologic 
evaluation has been the standard for 
evaluation of abnormal cervical cytology 
since the 1960s. Colposcopy with 
biopsy is undertaken in women with 
persistent cytological abnormalities or 
concerning cytology. This allows for 
further characterization of pre-
cancerous or cancerous lesions and 
guides management. Detection of high-
grade cervical disease through 
colposcopy has been estimated to range 
from 50-80%.1-3  
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Improving sensitivity of colposcopy has 
been undertaken by taking additional 
biopsies; however the optimum 
technique is unknown. Recent studies 
have explored various strategies. 
Additional directed biopsies from 
unique, suspicious appearing lesions 
improved sensitivity of detecting CIN3+ 
from 68.3% (1 biopsy) to 81.8% (2 
biopsies).4 Others have found the 
accuracy of colposcopically directed 
biopsy to be higher with 3 biopsies (up 
to 95.6%).5,6  Random biopsies at the 
squamocolumnar junction when no 
lesions are visible have been shown to 
detect 19.7% of CIN2+ disease with one 
biopsy,7 and 25.7% of CIN3+ with four 
biopsies (one in each cervical 
quadrant).8 
Further techniques to improve the 
sensitivity of cervical high-grade disease 
and cancer detection include the use of 
digital imaging technologies. We 
reviewed the use of a cervical imaging 
system (CIS) to determine its impact in 
identifying CIN2+ beyond initial clinician 
directed biopsy. 
Methods 
Participants included women 18 years of 
age or older who were referred to the 
colposcopy clinic at the University of 
Iowa Hospital and Clinics according to 
established guidelines for evaluation of 
abnormal cervical cytology (atypical 
squamous cells (ASC) or greater) 
between July 2008 and October 2010. 
The colposcopy clinic is a resident clinic 
staffed by 5 general gynecology 
attending physicians and one nurse 
practitioner during the study enrollment 
period. The nurse practitioner had 
greater than 15 years of colposcopy 
experience, 2 of the gynecologists had 
at least 10 years of colposcopy 
experience, and 3 of the gynecologists 
had less than 10 years of colposcopy 
experience. All resident colposcopy 
exams were completed with direct real-
time supervision by a gynecology 
attending physician.  A total of 195 
women aged 20 years and older were 
enrolled in the Institutional Review 
Board approved study.  
The LUMA Cervical Imaging System 
(SpectraScience, Inc) was approved by 
the US FDA as an adjunct to colposcopy 
to map the cervix and identify high risk 
lesions with spectroscopy to identify 
high-grade neoplastic lesions of 2 mm 
or more.9 LUMA exploits the inherent 
differences of light reflectance and 
fluorescence between normal and 
neoplastic tissue to map the ectocervix 
and identify areas with high probability 
of being neoplastic with an increase of 
at least 25% in the true-positive biopsy 
rate in prior studies.9-11 The FDA 
approved this device in March 2006, 
however the device lost funding in 2010 
(concluding the study).  
Women referred for colposcopy 
underwent a CIS scan prior to 
undergoing a standard colposcopic 
evaluation. The results of the CIS scan 
were revealed after the colposcopist had 
completed colposcopy and committed to 
any colposcopically directed biopsy 
sites. After sites for colposcopically 
directed biopsies had been annotated 
on the CIS computer screen, the results 
of the CIS scan were unmasked and 
any additional biopsy sites were 
identified based on the CIS result. 
Colposcopists were instructed to take at 
least one biopsy from any area identified 
as a high probability for CIN 2+ based 
on the CIS result in addition to areas 
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identified during standard colposcopy. 
Biopsy was not required in cases where 
the colposcopic impression was normal 
or low-grade squamous intraepithelial 
lesion (LSIL) corresponding to cervical 
intraepithelial neoplasia (CIN) I or less. 
In every case the clinician was asked to 
complete endocervical sampling 
(endocervical Pap smear or 
endocervical curettage). All biopsy 
specimens were reviewed by 
Pathologists at the University of Iowa 
Hospital and Clinics according to 
standard institutional protocol. All 
patients were informed of the results 
and management recommendations 
based on the American Society for 
Colposcopy and Cervical Pathology 
(ASCCP) guidelines at that time and 
underwent further excisional procedure 
if clinically indicated.  
Results were collected and categorized 
according to presence and level of 
cervical dysplasia; CIN 2, CIN 3 
adenocarcinoma in-situ (ACIS) and 
invasive cancer were considered CIN2+ 
disease. Additional information including 
age, self-identification as a current 
tobacco smoker, and referral Pap smear 
was collected by chart review. 
Exclusion criteria included pregnancy 
through 6 weeks post-partum, previous 
hysterectomy, history of diethylstilbestrol 
exposure, cervical biopsy or therapeutic 
procedure since the referral cervical 
cytology, cervical cytology test within the 
prior seven days, use of vaginal 
medications within the last 48 hours or 
photosensitizing agents within 72 hours, 
history of photosensitivity or other 
diseases affected by UV radiation, or an 
observable and untreated gynecological 
infection. 
Results 
195 women were enrolled in the study. 
There were 14 (7.2%) women where the 
CIS was not utilized during the exam, 
including: device unable to focus (n=6), 
device failure (n=5), withdrew consent 
(n=2), and bleeding (n=1). Thus there 
were 181 subjects eligible for 
comparison. 
The median age of women in the study 
was 27 years old (range 20 to 66); the 
majority were 30 years old or less 118 of 
181 (65%), with 20 women age 40 to 49 
years old, and 9 women age 50 years 
old or greater. Review of Pap smear 
results preceding colposcopy identified 
44 of 181 (24%) women were referred 
for high-grade intraepithelial lesions 
(HSIL). However, the most common 
indication for colposcopy was for low-
grade intraepithelial lesions (LSIL) 91 of 
181 (50%) (Table 1).  
Fifty women were found to have CIN2+ 
including 2 women with invasive 
squamous cell carcinoma. Clinician 
directed biopsy detected 45 (90%) of the 
CIN2+ identified. Additional CIS directed 
biopsy identified CIN2+ in 5 women 
which were not detected by clinician 
annotation; including CIN 2 in 3 women 
and CIN 3 in 2 women (Table 2). 
Referral Pap smears included 3 for 
ASC, and 1 each for LSIL and HSIL.  
The CIS identified CIN2+ in many cases 
also noted by the clinician; however it 
did not detect disease in nearly half, 24 
of 50 (48%) of cases identified by the 
clinician. Clinician and CIS identified 
one case of invasive cancer that was 
diagnosed with biopsy. 
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Table 1. Cases, by Age, smoking status and referral Pap smear 
Age years  
20-24 64 
25-29 54 
30-39 36 
40-49 18 
50 or older 9 
Current Smoker  
Yes 58 
No 123 
Referral Pap Smear  
ASC: atypical squamous cells 36 
ASC-H: atypical squamous cells, cannot exclude high grade 10 
LSIL: low grade intraepithelial lesion 91 
HSIL: high grade intraepithelial lesion 44 
 
Table 2. CIN2+ cases detected by clinician, CIS, or both
Pathology 
Clinician directed biopsy (n) 
 
CIS directed biopsy (n) 
 
Clinician and CIS directed 
biopsy   (n) 
CIN 2 11 3 6 
CIN 3 13 2 14 
Invasive CA 0 0 1 
Totals 24 5 21 
CIS: cervical imaging system 
CIN: cervical intraepithelial neoplasia 
n: number 
 
However, only the clinician took a 
biopsy of the CIN3+ in a patient with 
invasive cancer detected on subsequent 
loop electrical excision procedure 
(LEEP).  
Two hundred and forty-eight total 
biopsies were taken (Figure 1). Clinician 
directed biopsy collected 180 total 
biopsies (0 to 5 biopsies directed by 
clinician for each patient) (Table 3). 
Thus, one case of CIN2+ was identified 
for every 4 clinician biopsies. 
CIS directed biopsy collected 68 
additional biopsies (additional 0 to 2 
directed by CIS for each patient) to 
identify the 5 additional cases of CIN2+.  
Thus, approximately 14 biopsies 
directed by CIS were required to find 
each additional case of CIN2+ disease 
not identified by clinician directed 
biopsy.
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Figure 1. CIN2+ detected by biopsy from clinician, cervical imaging system (CIS) 
or both 
Table 3. Clinician directed biopsies 
Provider years of 
colposcopy experience 
0 biopsy 1 biopsy 2 biopsy 3 biopsy 4+ biopsy 
20 years 
nurse practitioner 
64 patients 39 patients 2 patients 0 0 
10 or greater years  
2 gynecology attendings 
15 patients 21 patients 16 patients 9 patients 2 patients 
(1 each 
with 4 and 5 
biopsies) 
Less than 10 years 
3 gynecology attendings 
13 patients 9 patients 3 patients   
  
 
Among the additional 5 cases of CIN2+ 
identified by CIS, 0 to 1 clinician 
directed biopsies were performed and 1 
to 2 additional CIS directed biopsies 
were performed. The additional 5 cases 
were identified with 1 to 3 total biopsies 
performed for each patient (Table 4). 
 
Total biopsies for each patient (clinician 
directed and additional CIS directed) 
range from 0 (endocervical sampling 
only) to 5. No cases of CIN2+ were 
identified based on endocervical 
sampling only. The majority of patients 
had 0 to 2 biopsies performed; 29 
patients had 3 or more biopsies. 
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Table 4. Additional 5 patients with CIN2+ identified by CIS 
 Provider experience Clinician Biopsies (n) Additional CIS biopsies (n) Total Biopsies (n) 
CIN 2 Less than 10 years 1 2 3 
CIN 2 20 years 1 1 2 
CIN 2 20 years 0 1 1 
CIN 3 20 years 1 1 2 
CIN 3 20 years 0 1 1 
CIS: cervical imaging system 
CIN: cervical intraepithelial neoplasia   
n: number 
 
All of the patients with CIN 2 were less 
than 50 years old: 6 were 21 to 24 years 
old, 8 were 25 to 30 years old, and 6 
were 31 to 41 years old. Subsequent 
LEEP was performed in 17 patients of 
which 1 was normal, 4 revealed CIN I, 5 
revealed CIN 2, 6 revealed CIN 3, and 1 
revealed ACIS. Two of the remaining 
patients were treated with ablation 
therapy (1 cryotherapy, 1 laser) and 1 
patient was followed with serial 
colposcopy. All three had return to 
normal cytology at 12 months. 
The 29 patients with CIN 3 were 21 to 
54 years old, with 8 patients age 31 
years old or greater. Twenty-five of 29 
patients with CIN 3 were treated with 
LEEP of which 2 revealed CIN I, 7 
revealed CIN 2, 14 revealed CIN 3, 1 
revealed invasive squamous cell cancer, 
and 1 revealed HSIL with extensive 
cautery (unable to grade further). Two of 
the remaining patients were treated with 
ablation therapy (1 cryotherapy, l laser). 
One patient was scheduled for laser but 
was pregnant when she presented for 
treatment and transferred care to her 
local provider, and 1 patient underwent 
a hysterectomy concurrent with bowel 
resection for Crohn’s disease with 
residual CIN I identified on pathology. 
Discussion 
Comparing the overall effectiveness of 
screening and diagnostic paradigms that 
incorporate different strategies is 
difficult. To insure the CIS was used as 
an adjunct to colposcopy, the results of 
the CIS scan were not displayed until 
after the colposcopic examination was 
complete and the colposcopist had 
committed to sites for colposcopically 
directed biopsies. Additional CIS 
directed biopsies increased the 
detection of cervical high-grade disease 
by 10% among women referred to 
colposcopy for abnormal cytology 
compared to colposcopy alone, with 
approximately 14 additional biopsies 
required for each additional CIN2+ 
detected. Specifically reviewing the 5 
cases of CIN2+ identified by CIS, 1 to 3 
total biopsies were performed for each 
patient.   
Forty-five patients in this study received 
endocervical sampling only - without 
biopsy at the time of colposcopy which 
may have resulted in decreased 
detection of CIN2+ as a subsequent 
excision procedure was not required as 
a gold standard.  As identified by others, 
both random and directed additional 
biopsies increase the sensitivity of 
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traditional colposcopy.4-8 
What is not clear is whether the 
additional cases identified represent 
clinically significant disease. We agree 
with Huh et al. that colposcopy misses 
clinically significant (as well as clinically 
insignificant) disease.7 We did not 
further evaluate patients with diagnostic 
procedures to determine if underlying 
cervical disease missed by the clinician 
with or without additional biopsies per 
the CIS was present. We suspect that 
the sensitivity of the clinicians in our 
department is similar to other academic 
departments. Furthermore, we did not 
confirm the histological diagnosis of CIN 
2 as the use of biomarkers including p16 
was not the standard of care at the time 
of this study. Thus, cases may have 
been misclassified. However, these 
dilemmas reflect the overall clinical 
challenge of risk based assessment and 
improving the sensitivity of colposcopy.  
Our study evaluated a generally young 
patient population with a significant 
number of patients aged less than 30 
years; with only 29 patients age 40 
years old or greater. Given that most 
cervical cancer is diagnosed in patients 
in the fourth decade,12 we suspect the 
overall sensitivities of clinician and CIS 
directed biopsy would have been higher 
if the population in our study was older. 
Additional limitations of this study 
include the CIS was not reliable and not 
adaptable to various cervical 
evaluations. The CIS is limited to scan 
and analyze a 2D plane.9 In our series, 
12 (of 195) of women were unable to 
undergo evaluation with CIS due to 
machine malfunction or limitation 
(additionally 2 withdrew – for a total of 
14 exclusions). Furthermore, while the 
CIS agreed with the clinician directed 
biopsy in many cases, it did not identify 
CIN2+ in 24 of 50 (48%) cases where 
the clinician biopsy confirmed CIN2+. 
This is lower than previous reports for 
the CIS.9-11  
While, colposcopy and biopsy are the 
standard methods of diagnosing high-
grade lesions of the cervix, it is not 
without limitations. Even highly 
experienced colposcopists can vary 
greatly in their colposcopic 
interpretations. Thus, histology obtained 
by biopsy is paramount in the detection 
of cervical dysplasia. Based on the data 
in this study, the use of a CIS does not 
appear to be better than performing 
additional random biopsies. Our study is 
particularly relevant as practitioners 
develop best practice guidelines 
including implementation of standards to 
identify optimal diagnostic techniques 
and adjunct technology to improve upon 
current practice. 
Funding: This study was funded by the 
University of Iowa Foundation - John and Mary 
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